Compounds > ropinirole
Page last updated: 2024-11-04

ropinirole and Autosomal Dominant Juvenile Parkinson Disease

ropinirole has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 23 studies

Research Excerpts

ExcerptRelevanceReference
"Chronic pain is a common and undertreated nonmotor symptom in Parkinson's disease (PD)."1.62D2 receptor activation relieves pain hypersensitivity by inhibiting superficial dorsal horn neurons in parkinsonian mice. ( Luan, YW; Tang, DL; Xiao, C; Zhou, CY, 2021)
"Ropinirole is a pharmacologically active agent used in the treatment of Parkinson's disease (PD) that directly acts on dopamine receptors."1.39Ropinirole protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced neurotoxicity in mice via anti-apoptotic mechanism. ( Oh, MS; Park, G; Park, YJ; Yang, HO, 2013)
" Study of pharmacokinetic parameters (AUC, C(max), and T(max)) revealed a greater and more extended release of ropinirole from nanoemulsion gel compared to that from a conventional gel (RPG) and oral marketed tablet (Ropitor)."1.38Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation. ( Ahmad, FJ; Azeem, A; Iqbal, Z; Khar, RK; Negi, LM; Talegaonkar, S, 2012)

Research

Studies (23)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's13 (56.52)29.6817
2010's8 (34.78)24.3611
2020's2 (8.70)2.80

Authors

AuthorsStudies
Tang, DL1
Luan, YW1
Zhou, CY1
Xiao, C1
Naz, F1
Fatima, M1
Naseem, S1
Khan, W1
Mondal, AC1
Siddique, YH1
Shin, E1
Lisci, C1
Tronci, E1
Fidalgo, C1
Stancampiano, R1
Björklund, A1
Carta, M2
Yang, C1
Zhang, JR1
Chen, L1
Ge, SN1
Wang, JL1
Yan, ZQ1
Jia, D1
Zhu, JL1
Gao, GD1
Tsuchioka, A1
Oana, F1
Suzuki, T1
Yamauchi, Y1
Ijiro, T1
Kaidoh, K1
Hiratochi, M1
Negro, S1
Boeva, L1
Slowing, K1
Fernandez-Carballido, A1
Garcia-García, L1
Barcia, E1
Synofzik, M1
Asmus, F1
Reimold, M1
Schöls, L1
Berg, D1
Lane, EL1
Dunnett, SB1
Azeem, A1
Talegaonkar, S1
Negi, LM1
Ahmad, FJ1
Khar, RK1
Iqbal, Z1
Park, G1
Park, YJ1
Yang, HO1
Oh, MS1
Tel, BC1
Zeng, BY1
Cannizzaro, C1
Pearce, RK2
Rose, S1
Jenner, P2
Muriel, MP1
Orieux, G1
Hirsch, EC1
Hill, MP1
Bezard, E1
McGuire, SG1
Crossman, AR3
Brotchie, JM3
Michel, A1
Grimée, R1
Klitgaard, H1
Ravenscroft, P2
Chalon, S1
Silverdale, MA1
Nicholson, SL1
Millan, MJ1
Salamone, JD1
Carlson, BB1
Rios, C1
Lentini, E1
Correa, M1
Wisniecki, A1
Betz, A1
Lundblad, M1
Usiello, A1
Håkansson, K1
Fisone, G1
Cenci, MA1
Carta, AR1
Frau, L1
Lucia, F1
Pinna, A1
Annalisa, P1
Pontis, S1
Silvia, P1
Simola, N1
Nicola, S1
Schintu, N1
Nicoletta, S1
Morelli, M1
Micaela, M1
Fukuzaki, K1
Kamenosono, T1
Nagata, R1
Prikhojan, A1
Brannan, T1
Yahr, MD1
Masson, C1
Maratos, EC1
Jackson, MJ1

Reviews

2 reviews available for ropinirole and Autosomal Dominant Juvenile Parkinson Disease

ArticleYear
Ropinirole silver nanocomposite attenuates neurodegeneration in the transgenic Drosophila melanogaster model of Parkinson's disease.
    Neuropharmacology, 2020, 10-15, Volume: 177

    Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Antiparkinson Agents; Disease Models, Anima

2020
[Parkinson disease: diagnostic and therapeutic criteria].
    Presse medicale (Paris, France : 1983), 2001, Mar-03, Volume: 30, Issue:8

    Topics: Activities of Daily Living; Adult; Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Diagnosis,

2001

Other Studies

21 other studies available for ropinirole and Autosomal Dominant Juvenile Parkinson Disease

ArticleYear
D2 receptor activation relieves pain hypersensitivity by inhibiting superficial dorsal horn neurons in parkinsonian mice.
    Acta pharmacologica Sinica, 2021, Volume: 42, Issue:2

    Topics: Action Potentials; Animals; Chronic Pain; Dopamine Agonists; Dopamine Antagonists; Indoles; Male; Mi

2021
The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
    Neurobiology of disease, 2014, Volume: 62

    Topics: Amphetamine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Benzazepines; Buspirone; Disease

2014
Decreased HCN2 expression in STN contributes to abnormal high-voltage spindles in the cortex and globus pallidus of freely moving rats.
    Brain research, 2015, Aug-27, Volume: 1618

    Topics: Animals; Antiparkinson Agents; Cardiovascular Agents; Cerebral Cortex; Disease Models, Animal; Down-

2015
Duration of drug action of dopamine D2 agonists in mice with 6-hydroxydopamine-induced lesions.
    Neuroreport, 2015, Dec-16, Volume: 26, Issue:18

    Topics: Animals; Antiparkinson Agents; Apomorphine; Azepines; Benzothiazoles; Cabergoline; Corpus Striatum;

2015
Efficacy of Ropinirole-Loaded PLGA Microspheres for the Reversion of Rotenone- Induced Parkinsonism.
    Current pharmaceutical design, 2017, Volume: 23, Issue:23

    Topics: Animals; Antiparkinson Agents; Cell Line, Tumor; Cell Survival; Humans; Indoles; Insecticides; Lacti

2017
Sustained dopaminergic response of parkinsonism and depression in POLG-associated parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 2010, Jan-30, Volume: 25, Issue:2

    Topics: Affect; Depression; DNA Polymerase gamma; DNA-Directed DNA Polymerase; Dopamine Agents; Female; Huma

2010
Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat.
    Behavioural brain research, 2010, Nov-12, Volume: 213, Issue:1

    Topics: Animals; Antiparkinson Agents; Bromocriptine; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-I

2010
Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation.
    International journal of pharmaceutics, 2012, Jan-17, Volume: 422, Issue:1-2

    Topics: Administration, Cutaneous; Administration, Oral; Animals; Antiparkinson Agents; Biological Availabil

2012
Ropinirole protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced neurotoxicity in mice via anti-apoptotic mechanism.
    Pharmacology, biochemistry, and behavior, 2013, Volume: 104

    Topics: Animals; Antiparkinson Agents; Apoptosis; bcl-2-Associated X Protein; Behavior, Animal; Caspase 3; C

2013
Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets.
    Neuroscience, 2002, Volume: 115, Issue:4

    Topics: Animals; Antiparkinson Agents; Bromocriptine; Callithrix; Dopamine Uptake Inhibitors; Dyskinesia, Dr

2002
Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:6

    Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Cytoplasm; Drug Combinations; Indoles; Le

2002
Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.
    Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:11

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Antiparkinson Agents; Callit

2003
Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
    Experimental neurology, 2004, Volume: 185, Issue:1

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine A

2004
Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.
    Experimental neurology, 2004, Volume: 188, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzopyrans; Brain; Callithrix; Disease Model

2004
Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of Parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243.
    Behavioural brain research, 2005, Jan-30, Volume: 156, Issue:2

    Topics: Analysis of Variance; Animals; Cholinergic Agents; Disease Models, Animal; Dopamine Agonists; Dose-R

2005
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Experimental neurology, 2005, Volume: 194, Issue:1

    Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal

2005
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
    Synapse (New York, N.Y.), 2008, Volume: 62, Issue:7

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Corpus St

2008
Effects of ropinirole on various parkinsonian models in mice, rats, and cynomolgus monkeys.
    Pharmacology, biochemistry, and behavior, 2000, Volume: 65, Issue:3

    Topics: Animals; Antiparkinson Agents; Bromocriptine; Catalepsy; Dopamine Agonists; Indoles; Macaca fascicul

2000
Comparative effects of repeated administration of dopamine agonists on circling behavior in rats.
    Journal of neural transmission (Vienna, Austria : 1996), 2000, Volume: 107, Issue:10

    Topics: Animals; Benzothiazoles; Brain; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration S

2000
[Parkinson's disease].
    Presse medicale (Paris, France : 1983), 2001, Mar-03, Volume: 30, Issue:8

    Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Catechols; Depressive Disorder; Diagnosis, Different

2001
Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).
    Movement disorders : official journal of the Movement Disorder Society, 2001, Volume: 16, Issue:4

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Dose-Respon

2001